Featured Research

from universities, journals, and other organizations

Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer

Date:
April 12, 2001
Source:
Rush Presbyterian St. Luke's Medical Center
Summary:
Breast cancer researchers at Rush-Presbyterian-St. Luke's Medical Center in Chicago have begun testing a new therapy that targets the blood vessels that feed breast cancer tumors. This new antiangiogenic therapy, called rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) seeks to block cancer's ability to form new blood vessels that feed the tumor.

Breast cancer researchers at Rush-Presbyterian-St. Luke's Medical Center in Chicago have begun testing a new therapy that targets the blood vessels that feed breast cancer tumors.

This new antiangiogenic therapy, called rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) seeks to block cancer's ability to form new blood vessels that feed the tumor.

Antiangiogenic therapy is a relatively new form of cancer treatment using drugs called angiogenesis inhibitors' that specifically halt new blood vessel growth and starve a tumor by cutting off its blood supply.

"If a tumor develops but has no blood supply, it will typically only grow to the size of a small pea," said principle investigator Dr. Melody Cobleigh, director of the Comprehensive Breast Center at Rush-Presbyterian-St. Luke's Medical Center in Chicago.

However, if the tumor is not detected and treated, eventually a few cancer cells gain the ability to produce proteins known as angiogenic growth factors. These 'growth factors' are released by the tumor into nearby tissues and they stimulate new blood vessels to sprout from existing healthy blood vessels, into the tumor. The tumor is then able to rapidly expand in size.

Patients enrolled in the trial at Rush will be randomly assigned to one of two treatment groups: one group will receive chemotherapy that is known to work against breast cancer. Another group will receive rhuMAb VEGF intravenously and chemotherapy.

RhuMAb VEGF was studied in women with breast cancer who had worsened on chemotherapy. Those early studies produced promising results. Researchers hope that by combining it with chemotherapy, they will get a better result than by using chemotherapy alone. The chemotherapy will attack the tumor while the rhuMAb VEGF will squeeze its blood supply.

Currently, approximately 20 anti-angiogenesis inhibitors are being tested in human cancer patients in clinical trials but there are no such drugs approved for clinical use by the Food and Drug Administration. Approximately 6,500 patients have taken one of these anti-angiogenic drugs to treat cancer.

Anti-angiogenesis inhibitors are also promising, according to the National Cancer Institute, because they are not as likely to cause bone marrow suppression, gastrointestinal symptoms, or hair loss -- symptoms characteristic of standard chemotherapy treatments. Additionally, these therapies target normal endothelial cells, which are genetically stable, so drug resistance may not develop. So far, resistance has not been a major problem in long-term animal studies or in preliminary clinical trials.

For more information about angiogenesis inhibitors, visit the National Cancer Insitutes' webpage at: http://cancertrials.nci.nih.gov/news/angio/fsangio.html

Rush-Presbyterian-St. Luke's Medical Center includes the 809-bed Presbyterian-St. Luke's Hospital; 154-bed Johnston R. Bowman Health Center for the Elderly; Rush University (Rush Medical College, College of Nursing, College of Health Sciences and Graduate College); and seven Rush Institutes providing diagnosis, treatment and research into leading health problems. The medical center is the tertiary hub of the Rush System for Health, a comprehensive healthcare system capable of serving about two million people through its outpatient facilities and five member hospitals.


Story Source:

The above story is based on materials provided by Rush Presbyterian St. Luke's Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush Presbyterian St. Luke's Medical Center. "Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer." ScienceDaily. ScienceDaily, 12 April 2001. <www.sciencedaily.com/releases/2001/04/010412081112.htm>.
Rush Presbyterian St. Luke's Medical Center. (2001, April 12). Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2001/04/010412081112.htm
Rush Presbyterian St. Luke's Medical Center. "Rush Studying Antiangiogenic Therapy To Treat Metastatic Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2001/04/010412081112.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins